Menu
Search icon
  1. Home Page
    2. ›
  2. Counties
    3. ›
  3. Kings
    4. ›
  4. 11209
    5. ›
  5. THE NARROWS INSTITUTE FOR BIOMEDICAL RESEARCH, INC.

THE NARROWS INSTITUTE FOR BIOMEDICAL RESEARCH, INC.

Company claim

Is this your business?

Get access!

Company Details

Name: THE NARROWS INSTITUTE FOR BIOMEDICAL RESEARCH, INC.
Jurisdiction: New York
Legal type: DOMESTIC NOT-FOR-PROFIT CORPORATION
Status: Active
Date of registration: 12 Jul 1990 (35 years ago)
Entity Number: 1460392
ZIP code: 11209
County: Kings
Place of Formation: New York
Address: MEDICAL CENTER, 800 POLY PLACE, BROOKLYN, NY, United States, 11209

DOS Process Agent

Name Role Address
DR. WILLIAM L. GREEN DOS Process Agent MEDICAL CENTER, 800 POLY PLACE, BROOKLYN, NY, United States, 11209

Unique Entity ID

A UEI is a government-provided number, like a tax ID number, that’s used to identify businesses eligible for federal grants, awards and contracts.

Note: In April 2022, the federal government replaced its old identifier of choice, the Data Universal Numbering System (DUNS) number, with a government-issued UEI. Now all the federal government’s Integrated Award Environment systems use UEI numbers instead of DUNS numbers. So any entity doing business with the federal government must register for a UEI.

Unique Entity ID:
F23LDFFMGTZ6
CAGE Code:
1Q440
UEI Expiration Date:
2026-02-04

Business Information

Activation Date:
2025-02-06
Initial Registration Date:
2007-10-02

Commercial and government entity program

The The Commercial And Government Entity Code (CAGE) is assigned by the Department of Defense's Defense Logistics Agency (DLA) and represents your company's physical address for GSA's mailings, payments, and administrative records.

Note: A CAGE Code enables a company to contract with the U.S. government, allowing bid on government contracts and to receive government payments. Also for business this means that it's a Verified business entity and Has a validated physical address.

CAGE number:
1Q440
Status:
Obsolete
Type:
Non-Manufacturer
CAGE Update Date:
2024-03-18
SAM Expiration:
2025-03-14

Contact Information

POC:
BETHANNE WENZEL
Phone:
+1 718-836-6600
Fax:
+1 718-567-4032

Form 5500 Series

Employer Identification Number (EIN):
113059470
Plan Year:
2023
Number Of Participants:
38
Sponsors Telephone Number:
7188366600
File:
View File
Plan Year:
2022
Number Of Participants:
37
Sponsors Telephone Number:
7188366600
File:
View File
Plan Year:
2021
Number Of Participants:
41
Sponsors Telephone Number:
7188366600
File:
View File
Plan Year:
2020
Number Of Participants:
37
Sponsors Telephone Number:
7188366600
File:
View File
Plan Year:
2019
Number Of Participants:
37
Sponsors Telephone Number:
7188366600
File:
View File

Filings

Filing Number Date Filed Type Effective Date
011204000787 2001-12-04 CERTIFICATE OF MERGER 2001-12-04
C161839-9 1990-07-12 CERTIFICATE OF INCORPORATION 1990-07-12

USAspending Awards / Contracts

Procurement Instrument Identifier:
V630D95073
Link:
View Award on USAspending website
Award Or Idv Flag:
AWARD
Award Type:
PO
Action Obligation:
16215.63
Base And Exercised Options Value:
16215.63
Base And All Options Value:
16215.63
Awarding Agency Name:
Department of Veterans Affairs
Performance Start Date:
2009-09-11
Description:
PROFESSIONAL, ADMIN, AND MANAGEMENT SUPPORT SVC
Product Or Service Code:
R699: OTHER ADMINISTRATIVE SUPPORT SVCS
Procurement Instrument Identifier:
DJBBROHUB30758
Link:
View Award on USAspending website
Award Or Idv Flag:
AWARD
Award Type:
PO
Action Obligation:
500.00
Base And Exercised Options Value:
500.00
Base And All Options Value:
500.00
Awarding Agency Name:
Department of Justice
Performance Start Date:
2008-09-29
Description:
MRI SERVICES GIVEN TO INMATES AT MDC BROOKLYN
Naics Code:
621512: DIAGNOSTIC IMAGING CENTERS
Product Or Service Code:
Q526: MEDICAL/PSYCH CONSULTATION SVCS
Procurement Instrument Identifier:
DJBHUB30745
Link:
View Award on USAspending website
Award Or Idv Flag:
AWARD
Award Type:
PO
Action Obligation:
2000.00
Base And Exercised Options Value:
2000.00
Base And All Options Value:
2000.00
Awarding Agency Name:
Department of Justice
Performance Start Date:
2008-09-22
Description:
MRI SERVICES GIVEN TO INMATES AT MDC BROOKLYN
Naics Code:
621512: DIAGNOSTIC IMAGING CENTERS
Product Or Service Code:
Q522: RADIOLOGY SERVICES

USAspending Awards / Financial Assistance

Date:
2022-08-19
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
RESCUE OF AUTOIMMUNE-ASSOCIATED LONG QT SYNDROME BY DECOY PEPTIDES - PROJECT SUMMARY/ABSTRACT AUTOIMMUNITY IS INCREASINGLY RECOGNIZED AS A NOVEL PATHOGENIC MECHANISM FOR CARDIAC ARRHYTHMIAS. SEVERAL ARRHYTHMOGENIC AUTOANTIBODIES HAVE BEEN IDENTIFIED, CROSS-REACTING WITH DIFFERENT TYPES OF SURFACE PROTEINS CRITICALLY INVOLVED IN CARDIOMYOCYTE ELECTROPHYSIOLOGY, PRIMARILY ION CHANNELS (AUTOIMMUNE CARDIAC CHANNELOPATHIES). SPECIFICALLY, SOME OF THESE AUTOANTIBODIES CAN PROLONG THE ACTION POTENTIAL DURATION, LEADING TO ACQUIRED LONG-QT SYNDROME (LQTS), A CONDITION KNOWN TO INCREASE THE RISK OF LIFE-THREATENING VENTRICULAR ARRHYTHMIAS, PARTICULARLY TORSADES DE POINTES (TDP) AND SUDDEN CARDIAC DEATH. THE MOST INVESTIGATED FORM OF AUTOIMMUNE LQTS IS ASSOCIATED WITH THE PRESENCE OF CIRCULATING ANTI-RO/SSA ANTIBODIES (ANTI-RO ABS), FREQUENTLY FOUND IN PATIENTS WITH AUTOIMMUNE DISEASES, BUT ALSO IN A SIGNIFICANT PROPORTION OF APPARENTLY HEALTHY SUBJECTS IN THE GENERAL POPULATION. ACCUMULATING EVIDENCE INDICATES THAT ANTI-RO ABS CAN MARKEDLY DELAY VENTRICULAR REPOLARIZATION VIA A DIRECT INHIBITORY CROSS-REACTION WITH THE EXTRACELLULAR PORE REGION OF THE HUMAN ETHER-A-GO-GO RELATED GENE K+ CHANNEL (HERG-K+), RESULTING IN A HIGHER PROPENSITY FOR ANTI-RO ABS-POSITIVE SUBJECTS TO DEVELOP LQTS AND VENTRICULAR ARRHYTHMIAS/TDP. RECENT POPULATION DATA DEMONSTRATE THAT THE RISK OF LQTS IN SUBJECTS WITH CIRCULATING ANTI-RO ABS IS SIGNIFICANTLY INCREASED, INDEPENDENT OF A HISTORY OF OVERT AUTOIMMUNE DISEASES. HERE, WE HYPOTHESIZE THAT DECOY PEPTIDES, DESIGNED TO MIMIC THE CROSS- REACTIVE B-CELL EPITOPE PRESENT ON BOTH RO/SSA ANTIGEN AND HERG-K+ CHANNEL S5-S6 PORE REGION, CAN NEUTRALIZE ANTI-RO ABS AND THUS NORMALIZE OR PREVENT QTC PROLONGATION. SUCH DECOY PEPTIDES ARE THEREFORE INNOVATIVE THERAPEUTIC TOOLS FOR ANTI-RO ABS INDUCED LQTS, ASSOCIATED TDP AND SUDDEN CARDIAC DEATH. IN THIS PROJECT, WE AIM TO DEVELOP THESE TOOLS AND TEST THE MOLECULAR, DECOY PEPTIDES HYPOTHESIS WITH 3 AIMS: 1) VALIDATE THE CROSS-REACTIVE EPITOPE HYPOTHESIS AND OPTIMIZE THE DECOY MOLECULE INTO A VALID BIOLOGIC DRUG CANDIDATE; 2) NORMALIZE QTC PROLONGATION BY THE ADMINISTRATION OF DECOY PEPTIDES TO AN IN VIVO ANIMAL MODEL OF AUTOIMMUNE ASSOCIATED LQTS AND 3) INVESTIGATE THE ELECTROPHYSIOLOGICAL MECHANISMS BY WHICH THE DECOY PEPTIDES NORMALIZE QTC PROLONGATION ON THE SURFACE ECG AT THE CARDIOMYICYTE LEVEL. COLLECTIVELY, THE NEW DECOY PEPTIDES DEVELOPED IN THIS APPLICATION MAY ILLUMINATE HOW ANTI-RO ABS CONTRIBUTE TO THE PUBLIC HEALTH BURDEN IMPOSED BY CARDIAC ARRHYTHMIAS. IN ADDITION, THIS RESEARCH COULD ACHIEVE NEW UNDERSTANDING OF PATHOPHYSIOLOGIC MECHANISMS OF ANTI-RO ABS AND OPEN A NEW THERAPEUTIC DIRECTION FOR MITIGATING THIS BURDEN, INCLUDING THE POSSIBILITY OF ADVANCING OUR DECOY PEPTIDE THERAPY TOWARDS A LICENSED DRUG. FINALLY, A NEW CONCEALED RISK FACTOR CONTRIBUTING TO LIFE-THREATENING VENTRICULAR ARRHYTHMIAS AND SUDDEN CARDIAC DEATH EVENTS IN THE GENERAL POPULATION MAY BE REVEALED AND TREATED.
Obligated Amount:
1771056.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2021-06-11
Link:
View on USAspending
Awarding Agency Name:
Department of Defense
Transaction Description:
CARDIAC MANIFESTATIONS IN MYOTONIC DYSTROPHY TYPE 1: ARRHYTHMIA MECHANISMS AND NOVEL THERAPEUTIC APPROACHES INCLUDE TITLE IN THE AWARD AND CORRECT THE RESEARCH PROGRAM DATA
Obligated Amount:
1189999.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2023-05-31
Link:
View on USAspending
Awarding Agency Name:
Department of Defense
Transaction Description:
GAIT COORDINATION AND STABILITY OF INDIVIDUALS LIVING WITH TRANSTIBIAL LIMB LOSS EXTEND THE PERIOD OF PERFORMANCE 1. PER SECTION 711 OF THE NATIONAL DEFENSE AUTHORIZATION ACT (NDAA) 2019, THE US ARMY MEDICAL RESEARCH ACQUISITION ACTIVITY (USAMRAA), US ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND (USAMRDC) TRANSFERRED TO THE DEFENSE HEALTH AGENCY (DHA) FROM THE U.S. ARMY EFFECTIVE 01 OCTOBER 2022. THIS MODIFICATION REFLECTS CHANGES CONSISTENT WITH THE TRANSFER TO DHA. 2. DIVISION II HAS BEEN UPDATED TO SUPERSEDE DIVISION III, PART 2, SECTION C, 2.B. ELECTRONIC PAYMENT INSTRUCTIONS
Obligated Amount:
0.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2020-05-19
Link:
View on USAspending
Awarding Agency Name:
Department of Defense
Transaction Description:
GAIT COORDINATION AND STABILITY OF INDIVIDUALS LIVING WITH TRANSTIBIAL LIMB LOSS.
Obligated Amount:
303145.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2019-04-16
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
MECHANISMS OF LIPOTOXIC ARRHYTHMIAS
Obligated Amount:
1525300.25
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00

Paycheck Protection Program

Date Approved:
2020-06-24
Loan Status:
Paid in Full
SBA Guaranty Percentage:
100
Initial Approval Amount:
351078
Current Approval Amount:
351078
Race:
Unanswered
Ethnicity:
Unknown/NotStated
Gender:
Unanswered
Veteran:
Unanswered
Forgiveness Amount:
354608.02

Reviews Leave a review

This company hasn't received any reviews.

Related by officers

No related officers

Related by address

No related companies by address

Date of last update: 15 Mar 2025

Sources: New York Secretary of State

Privacy policy Policy
About us About us
Contacts Contact us

© 2025 bizyork.com, Part of Big Data Integrated